Literature DB >> 17721269

The spectrum of morphomolecular abnormalities of the E-cadherin/catenin complex in pleomorphic lobular carcinoma of the breast.

David J Dabbs1, Malathy Kaplai, Mamatha Chivukula, Anisa Kanbour, Amal Kanbour-Shakir, Gloria J Carter.   

Abstract

Pleomorphic lobular carcinoma of the breast is a high nuclear grade variant of lobular carcinoma. E-cadherin, a tumor-invasion suppressor gene, codes for a transmembrane protein that functions in intercellular adhesion. The E-cadherin protein internal domain binds with alpha, beta, gamma, and p120 catenins to anchor the E-cadherin complex to the actin cytoskeleton of the cell. The E-cadherin gene is routinely mutated in lobular neoplasia. This study examines the morphomolecular spectrum of the components of the E-cadherin-catenin complex in lobular neoplasia. Fifteen cases of pleomorphic lobular neoplasia, 8 cases of classic lobular neoplasia and 4 ductal carcinomas were studied. Normal breast epithelium and invasive ductal carcinomas all showed intense linear cell membrane immunostaining with antibodies to E-cadherin, alpha, beta, gamma, and P120 catenins. Membrane immunostaining of the catenin antibodies in lobular neoplasia was negative, except for rare cases that displayed beaded or dotlike patterns. Cytoplasmic immunostaining patterns for all lobular lesions included coarse paranuclear granules of beta catenin or diffuse intense cytoplasmic staining for P120 catenin. These immunostaining patterns demonstrate that catenins alpha, beta, gamma, and p120 are routinely dislocated from the cell membrane into the cytoplasm in lobular neoplasia and that the disrupted catenin patterns parallel absence of membrane E-cadherin in all cases. The diffuse cytoplasmic immunostaining of p120 in lobular neoplasia may be useful diagnostically as a positive marker for lobular neoplasia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17721269     DOI: 10.1097/01.pai.0000213128.78665.3c

Source DB:  PubMed          Journal:  Appl Immunohistochem Mol Morphol        ISSN: 1533-4058


  7 in total

1.  Altered expression of p120catenin predicts poor outcome in invasive breast cancer.

Authors:  K Talvinen; J Tuikkala; M Nykänen; A Nieminen; J Anttinen; O S Nevalainen; S Hurme; T Kuopio; P Kronqvist
Journal:  J Cancer Res Clin Oncol       Date:  2010-02-12       Impact factor: 4.553

2.  Invasive lobular carcinoma with extracellular mucin production and HER-2 overexpression: a case report and further case studies.

Authors:  Jing Yu; Rohit Bhargava; David J Dabbs
Journal:  Diagn Pathol       Date:  2010-06-15       Impact factor: 2.644

Review 3.  [Practical problems in breast screening. Columnar cell lesions including flat epithelial atypia and lobular neoplasia].

Authors:  J Nährig
Journal:  Pathologe       Date:  2008-11       Impact factor: 1.011

Review 4.  Lobular Carcinoma In Situ.

Authors:  Hannah Y Wen; Edi Brogi
Journal:  Surg Pathol Clin       Date:  2017-12-08

5.  Morphologic subtypes of lobular carcinoma in situ diagnosed on core needle biopsy: clinicopathologic features and findings at follow-up excision.

Authors:  M Gabriela Kuba; Melissa P Murray; Kristen Coffey; Catarina Calle; Monica Morrow; Edi Brogi
Journal:  Mod Pathol       Date:  2021-04-06       Impact factor: 7.842

6.  BCL3 expression is strongly associated with the occurrence of breast cancer relapse under tamoxifen treatment in a retrospective cohort study.

Authors:  Piotr Czapiewski; Maximilian Cornelius; Roland Hartig; Thomas Kalinski; Johannes Haybaeck; Angela Dittmer; Jürgen Dittmer; Atanas Ignatov; Norbert Nass
Journal:  Virchows Arch       Date:  2022-01-12       Impact factor: 4.535

7.  Serial analysis of gene expression of lobular carcinoma in situ identifies down regulation of claudin 4 and overexpression of matrix metalloproteinase 9.

Authors:  Dengfeng Cao; Kornelia Polyak; Marc K Halushka; Hind Nassar; Nina Kouprina; Christine Iacobuzio-Donahue; Xinyan Wu; Saraswati Sukumar; Jessica Hicks; Angelo De Marzo; Pedram Argani
Journal:  Breast Cancer Res       Date:  2008-10-27       Impact factor: 6.466

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.